Abbate A, Salloum FN, Van Tassell BW, Vecile E, Toldo S, Seropian I, Mezzaroma E, Dobrina A (2011) Alterations in the interleukin-1/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse. PLoS ONE 6:e27923

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abbate A, Trankle CR, Buckley LF, Lipinski MJ, Appleton D, Kadariya D, Canada JM, Carbone S, Roberts CS, Abouzaki N et al (2020) Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-segment-elevation myocardial infarction. J Am Heart Assoc 9:e014941

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abbate A, Wohlford GF, Del Buono MG, Chiabrando JG, Markley R, Turlington J, Kadariya D, Trankle CR, Biondi-Zoccai G, Lipinski MJ et al (2022) Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials. Eur Heart J Cardiovasc Pharmacother 8:503–510

Article  PubMed  Google Scholar 

Adamo L, Staloch LJ, Rocha-Resende C, Matkovich SJ, Jiang W, Bajpai G, Weinheimer CJ, Kovacs A, Schilling JD, Barger PM, et al (2018) Modulation of subsets of cardiac B lymphocytes improves cardiac function after acute injury. JCI Insight 3

Aksentijevich I, Kastner DL (2011) Genetics of monogenic autoinflammatory diseases: past successes, future challenges. Nat Rev Rheumatol 7:469–478

Article  CAS  PubMed  Google Scholar 

Bageghni SA, Hemmings KE, Yuldasheva NY, Maqbool A, Gamboa-Esteves FO, Humphreys NE, Jackson MS, Denton CP, Francis S, Porter KE, et al (2019) Fibroblast-specific deletion of interleukin-1 receptor-1 reduces adverse cardiac remodeling following myocardial infarction. JCI Insight 5

Bajpai G, Bredemeyer A, Li W, Zaitsev K, Koenig AL, Lokshina I, Mohan J, Ivey B, Hsiao HM, Weinheimer C et al (2019) Tissue resident CCR2- and CCR2+ cardiac macrophages differentially orchestrate monocyte recruitment and fate specification following myocardial injury. Circ Res 124:263–278

Article  CAS  PubMed  PubMed Central  Google Scholar 

Befekadu R, Grenegård M, Larsson A, Christensen K, Ramström S (2022) Levels of soluble tumor necrosis factor receptor 1 and 2 are associated with survival after ST segment elevation myocardial infarction. Sci Rep 12:14762

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bettiol A, Silvestri E, Di Scala G, Amedei A, Becatti M, Fiorillo C, Lopalco G, Salvarani C, Cantarini L, Soriano A et al (2019) The right place of interleukin-1 inhibitors in the treatment of Behçet’s syndrome: a systematic review. Rheumatol Int 39:971–990

Article  CAS  PubMed  Google Scholar 

Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA Jr (1985) Interleukin-1 activation of vascular endothelium. Effects on procoagulant activity and leukocyte adhesion. Am J Pathol 121:394–403

CAS  PubMed  PubMed Central  Google Scholar 

Blanco-Domínguez R, de la Fuente H, Rodríguez C, Martín-Aguado L, Sánchez-Díaz R, Jiménez-Alejandre R, Rodríguez-Arabaolaza I, Curtabbi A, García-Guimaraes MM, Vera A, et al (2022) CD69 expression on regulatory T cells protects from immune damage after myocardial infarction. J Clin Invest 132

Blech M, Peter D, Fischer P, Bauer MM, Hafner M, Zeeb M, Nar H (2013) One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β. J Mol Biol 425:94–111

Article  CAS  PubMed  Google Scholar 

Bonaventura A, Vecchié A, Abbate A, Montecucco F (2020) Neutrophil extracellular traps and cardiovascular diseases: an update. Cells 9

Boraschi D, Tagliabue A (2013) The interleukin-1 receptor family. Semin Immunol 25:394–407

Article  CAS  PubMed  Google Scholar 

Brikos C, Wait R, Begum S, O’Neill LA, Saklatvala J (2007) Mass spectrometric analysis of the endogenous type I interleukin-1 (IL-1) receptor signaling complex formed after IL-1 binding identifies IL-1RAcP, MyD88, and IRAK-4 as the stable components. Mol Cell Proteom MCP 6:1551–1559

Article  CAS  PubMed  Google Scholar 

Buckley LF, Abbate A (2018) Interleukin-1 blockade in cardiovascular diseases: a clinical update. Eur Heart J 39:2063–2069

Article  CAS  PubMed  Google Scholar 

Bujak M, Dobaczewski M, Chatila K, Mendoza LH, Li N, Reddy A, Frangogiannis NG (2008) Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol 173:57–67

Article  PubMed  PubMed Central  Google Scholar 

Cai S, Zhao M, Zhou B, Yoshii A, Bugg D, Villet O, Sahu A, Olson GS, Davis J, Tian R (2023) Mitochondrial dysfunction in macrophages promotes inflammation and suppresses repair after myocardial infarction. J Clin Invest 133

Cao Z, Henzel WJ, Gao X (1996) IRAK: a kinase associated with the interleukin-1 receptor. Science (new York, NY) 271:1128–1131

Article  CAS  Google Scholar 

Carbone F, Nencioni A, Mach F, Vuilleumier N, Montecucco F (2013) Pathophysiological role of neutrophils in acute myocardial infarction. Thromb Haemost 110:501–514

Article  CAS  PubMed  Google Scholar 

Casadio R, Frigimelica E, Bossù P, Neumann D, Martin MU, Tagliabue A, Boraschi D (2001) Model of interaction of the IL-1 receptor accessory protein IL-1RAcP with the IL-1beta/IL-1R(I) complex. FEBS Lett 499:65–68

Article  CAS  PubMed  Google Scholar 

Chen C, Feng Y, Zou L, Wang L, Chen HH, Cai JY, Xu JM, Sosnovik DE, Chao W (2014) Role of extracellular RNA and TLR3-Trif signaling in myocardial ischemia-reperfusion injury. J Am Heart Assoc 3:e000683

Article  PubMed  PubMed Central  Google Scholar 

Chen X, Li Y, Li J, Liu T, Jiang Q, Hong Y, Wang Q, Li C, Guo D, Wang Y (2022) Qishen granule (QSG) exerts cardioprotective effects by inhibiting NLRP3 inflammasome and pyroptosis in myocardial infarction rats. J Ethnopharmacol 285:114841

Article  CAS  PubMed  Google Scholar 

Chen C, Wang J, Liu C, Hu J (2023) Cardiac resident macrophages: key regulatory mediators in the aftermath of myocardial infarction. Front Immunol 14:1207100

Article  CAS  PubMed  PubMed Central  Google Scholar 

Colantuoni M, Jofra Hernandez R, Pettinato E, Basso-Ricci L, Magnani L, Andolfi G, Rigamonti C, Finardi A, Romeo V, Soldi M, et al (2023) Constitutive IL-1RA production by modified immune cells protects against IL-1-mediated inflammatory disorders. Sci Transl Med 15:eade3856

Collins KH, Pferdehirt L, Saleh LS, Savadipour A, Springer LE, Lenz KL, Thompson DM Jr, Oswald SJ, Pham CTN, Guilak F (2023) Hydrogel encapsulation of genome-engineered stem cells for long-term self-regulating anti-cytokine therapy. Gels (Basel, Switzerland) 9

Colotta F, Re F, Muzio M, Bertini R, Polentarutti N, Sironi M, Giri JG, Dower SK, Sims JE, Mantovani A (1993) Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science (new York, NY) 261:472–475

Article  CAS  Google Scholar 

Davidson SM, Ferdinandy P, Andreadou I, Bøtker HE, Heusch G, Ibáñez B, Ovize M, Schulz R, Yellon DM, Hausenloy DJ et al (2019) Multitarget strategies to reduce myocardial ischemia/reperfusion injury: JACC review topic of the week. J Am Coll Cardiol 73:89–99

Article  PubMed  Google Scholar 

Del Buono MG, Damonte JI, Chiabrando JG, Markley R, Turlington J, Trankle CR, Kang L, Biondi-Zoccai G, Van Tassell BW, Abbate A (2022a) Effect of IL-1 blockade with Anakinra on heart failure outcomes in patients with anterior versus nonanterior ST elevation myocardial infarction. J Cardiovasc Pharmacol 79:774–780

Article  PubMed  PubMed Central  Google Scholar 

Del Buono MG, Damonte JI, Trankle CR, Kadariya D, Carbone S, Thomas G, Turlington J, Markley R, Canada JM, Biondi-Zoccai GG et al (2022b) Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction. Sci Rep 12:1254

Article  PubMed  PubMed Central  Google Scholar 

Del Buono MG, Damonte JI, Moroni F, Chiabrando JG, Markley R, Turlington J, Trankle CR, Kang L, Biondi-Zoccai G, Kontos MC et al (2023) Clinical and pharmacological implications of time to treatment with interleukin-1 blockade in ST-segment elevation myocardial infarction. J Pharmacol Exp Ther 386:156–163

Article  PubMed  Google Scholar 

Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, Abou-Khamis T, Michael LH, Rollins BJ, Entman ML, Frangogiannis NG (2005) CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 96:881–889

Article  CAS  PubMed  Google Scholar 

Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117:3720–3732

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dinarello CA (2018) Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev 281:8–27

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ding HS, Huang Y, Qu JF, Wang YJ, Huang ZY, Wang FY, Yi WJ, Liu XX (2023) Panaxynol ameliorates cardiac ischemia/reperfusion injury by suppressing NLRP3-induced pyroptosis and apoptosis via HMGB1/TLR4/NF-κB axis. Int Immunopharmacol 121:110222

Article  CAS  PubMed  Google Scholar 

Diwanji R, O’Brien NA, Choi JE, Nguyen B, Laszewski T, Grauel AL, Yan Z, Xu X, Wu J, Ruddy DA et al (2023) Targeting the IL1β pathway for cancer immunotherapy remodels the tumor microenvironment and enhances antitumor immune responses. Cancer Immunol Res 11:777–791

Article  CAS  PubMed  Google Scholar 

Duerschmied D, Suidan GL, Demers M, Herr N, Carbo C, Brill A, Cifuni SM, Mauler M, Cicko S, Bader M et al (2013) Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood 121:1008–1015

Article  CAS  PubMed  PubMed Central  Google Scholar 

El Sayed H, Kerensky R, Stecher M, Mohanty P, Davies M (2016) A randomized phase II study of Xilonix, a targeted therapy against interleukin 1α, for the prevention of superficial femoral artery restenosis after percutaneous revascularization. J Vasc Surg 63:133-141.e131

Article  PubMed  Google Scholar 

Emran T, Chowdhury NI, Sarker M, Bepari AK, Hossain M, Rahman GMS, Reza HM (2021) L-carnitine protects cardiac damage by reducing oxidative stress and inflammatory response via inhibition of tumor necrosis factor-alpha and interleukin-1beta against isoproterenol-induced myocardial infarction. Biomed Pharmacother 143:112139

Enzan N, Matsushima S, Ikeda S, Okabe K, Ishikita A, Yamamoto T, Sada M, Miyake R, Tsutsui Y, Nishimura R et al (2023) ZBP1 protects against mtDNA-induced myocardial inflammation in failing hearts. Circ Res 132:1110–1126

Article  CAS  PubMed  PubMed Central